MedPath

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Phase 3
Completed
Conditions
Head and Neck Cancer
Registration Number
NCT00003888
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for advanced head and neck cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy plus radiation therapy in treating patients who have advanced head and neck cancer.

Detailed Description

OBJECTIVES: I. Compare the progression free survival of patients with locally advanced, inoperable squamous cell carcinoma of the head and neck treated with cisplatin plus fluorouracil with or without docetaxel as a neoadjuvant to radiotherapy. II. Compare the response rate, response duration, toxicity, local symptoms, and time to disease progression of these treatment regimens in this patient population. III. Evaluate the quality of life in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to primary tumor site (oral cavity vs oropharynx vs hypopharynx vs larynx) and institution. Patients are randomized to one of two treatment arms. Arm I: Patients receive docetaxel IV over 1 hour, immediately followed by cisplatin IV over 1 hour on day 1 and fluorouracil (5-FU) IV as a continuous infusion on days 1-5. Arm II: Patients receive cisplatin IV over 1 hour on day 1 followed by 5-FU IV as a continuous infusion on days 1-5. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive radiotherapy following chemotherapy within 3-6 weeks of last course. Radiotherapy is administered 5 days a week for up to 7 weeks. Quality of life is assessed before treatment, at courses 2 and 4, and at 6 and 9 months. Patients are followed every 3 months for the first 2 years and then every 6 months until death.

PROJECTED ACCRUAL: A total of 348 patients will be accrued for this study within 24 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
359
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (44)

Institute of Oncology and Radiology of Serbia

Belgrade, Former Yugoslavia

CHR de Besancon - Hopital Jean Minjoz

🇫🇷

Besancon, France

Centre Hospital Regional Universitaire de Limoges

🇫🇷

Limoges, France

Centre Oscar Lambret

🇫🇷

Lille, France

Centre Leon Berard

🇫🇷

Lyon, France

CRLCC Nantes - Atlantique

🇫🇷

Nantes-Saint Herblain, France

CHR Hotel Dieu

🇫🇷

Nantes, France

Centre Antoine Lacassagne

🇫🇷

Nice, France

Martin Luther Universitaet

🇩🇪

Halle, Germany

Caritasklinik St. Theresia

🇩🇪

Saarbrucken, Germany

Mutterhaus der Borromaerinnen

🇩🇪

Trier, Germany

National Institute of Oncology

🇭🇺

Budapest, Hungary

Centro di Riferimento Oncologico - Aviano

🇮🇹

Aviano, Italy

Ospedale Santa Croce

🇮🇹

Cuneo, Italy

Istituti Fisioterapici Ospitalieri - Roma

🇮🇹

Rome, Italy

Ospedale di Circolo e Fondazione Macchi

🇮🇹

Varese, Italy

Academisch Medisch Centrum

🇳🇱

Amsterdam, Netherlands

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

Academisch Ziekenhuis Maastricht

🇳🇱

Maastricht, Netherlands

Institut Catala d'Oncologia - Hospital Duran i Reynals

🇪🇸

Barcelona, Spain

Hospital General de Jerez

🇪🇸

Jerez, Spain

Universidad de Santiago - Hospital de Conxo

🇪🇸

Santiago de Compostela, Spain

Hospital Clinico Universitario de Valencia

🇪🇸

Valencia, Spain

Landeskrankenhaus/Universitatskliniken Graz

🇦🇹

Graz, Austria

Allgemeines Krankenhaus der Stadt Wien

🇦🇹

Vienna, Austria

Kaiser Franz Josef Hospital

🇦🇹

Vienna, Austria

Institut Jules Bordet

🇧🇪

Brussels, Belgium

Centre Hospitalier Regional de la Citadelle

🇧🇪

Liege, Belgium

Algemeen Ziekenhuis Middelheim

🇧🇪

Antwerp, Belgium

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Clinique Universitaire De Mont-Godinne

🇧🇪

Mont-Godinne Yvoir, Belgium

Ahepa University Hospital

🇬🇷

Thessaloniki, Greece

Borsod-Abauj-Zemplen County Hospital

🇭🇺

Miskolc, Hungary

Szent Margit Hospital

🇭🇺

Budapest, Hungary

University Medical Center Nijmegen

🇳🇱

Nijmegen, Netherlands

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

🇵🇱

Warsaw, Poland

National Cancer Institute - Bratislava

🇸🇰

Bratislava, Slovakia

Ospedale San Giovanni

🇨🇭

Bellinzona, Switzerland

Istanbul University-Institute of Oncology

🇹🇷

Istanbul, Turkey

Kantonspital Aarau

🇨🇭

Aarau, Switzerland

Middlesex Hospital- Meyerstein Institute

🇬🇧

London, England, United Kingdom

Newcastle General Hospital

🇬🇧

Newcastle Upon Tyne, England, United Kingdom

Beatson Oncology Centre

🇬🇧

Glasgow, Scotland, United Kingdom

Charing Cross Hospital

🇬🇧

London, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath